WARRINGTON, Pa., May 4, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced that data from a preclinical study using KL4 surfactant demonstrated a favorable physiologic benefit and subsequent survival impact on treating Acute Lung Injury (ALI) in a well-established model for this severe respiratory condition. Discovery Labs’ novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for survival and normal respiratory function. The data were presented at the Pediatric Academic Societies Annual Meeting, which is internationally recognized as the largest, most relevant medical meeting dedicated to pediatric research.
